“Non-Small Cell Lung Cancer Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non-Small Cell Lung Cancer Market.
The Non-Small Cell Lung Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Non-Small Cell Lung Cancer Pipeline Report:
- Companies across the globe are diligently working toward developing novel Non-Small Cell Lung Cancer treatment therapies with a considerable amount of success over the years.
- Non-Small Cell Lung Cancer companies working in the treatment market are J INTS BIO BIO CO.,LTD, Mirati Therapeutics, MediLink Therapeutics Co., Ltd., BioNTech SE, Cellular Biomedicine Group, Shenzhen TargetRx, Inc, Iovance Biotherapeutics, Revolution Medicines, Inc., Genmab, Incyte Corporation, Daiichi Sankyo, Novartis Pharmaceutical, and others, are developing therapies for the Non-Small Cell Lung Cancer treatment
- Emerging Non-Small Cell Lung Cancer therapies in the different phases of clinical trials are- JIN-A03, MRTX1133, YL202, BNT116, C-TIL051, TGRX-326, LN-145, RMC-4630, GEN1046, Retifanlimab, DS-1062a, JDQ443, and others are expected to have a significant impact on the Non-Small Cell Lung Cancer market in the coming years.
- In August 2023, The United States Food and Drug Administration (FDA) has designated REQORSA® Immunogene Therapy (quratusugene ozeplasmid), the company's lead drug candidate, as an orphan drug for the treatment of small cell lung cancer (SCLC). Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.
- In August 2023, Earlier today, Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Oncology, Inc. announced the beginning of the REZILIENT3 trial (NCT05973773, Researching Zipalertinib In EGFR Non-Small Cell Lung Cancer Tumours), a global Phase 3 clinical trial examining the combination of zipalertinib and chemotherapy as a potential first-line treatment for adult patients
- In October 2022, A Phase Ib/II, Multicenter, Open-labele PlatformStudy of JDQ443 With Selected Combinations in Patients With Advanced Solid Tumours Carrying the KRAS G12CMutation was started by Novartis Pharmaceuticals. In this experiment, JDQ443 will be used as the "backbone" therapy in combination with one or more other therapies, or "partner(s)".
- In June 2022, In order to compare the effectiveness and safety of JDQ443 versus docetaxel in previously treated patients with locally advanced or metastatic KRAS G12C mutant non-small cell lung cancer, Novartis Pharmaceuticals started a randomised, controlled, open label, Phase III research.
Non-Small Cell Lung Cancer Overview
Non-small cell lung cancer (NSCLC) is a condition in which healthy lung cells rapidly divide and develop abnormally, causing a lesion, nodule, or tumour. These lesions, which can either be benign or cancerous, can appear anywhere in the lungs.
Get a Free Sample PDF Report to know more about Non-Small Cell Lung Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-pipeline-insight
Emerging Non-Small Cell Lung Cancer Drugs Under Different Phases of Clinical Development Include:
- JIN-A03: J INTS BIO BIO CO.,LTD
- MRTX1133: Mirati Therapeutics
- YL202: MediLink Therapeutics Co., Ltd.
- BNT116: BioNTech SE
- C-TIL051: Cellular Biomedicine Group
- TGRX-326: Shenzhen TargetRx, Inc
- LN-145: Iovance Biotherapeutics
- RMC-4630: Revolution Medicines, Inc.
- GEN1046: Genmab
- Retifanlimab: Incyte Corporation
- DS-1062a: Daiichi Sankyo
- JDQ443: Novartis Pharmaceuticals
Non-Small Cell Lung Cancer Route of Administration
Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Non-Small Cell Lung Cancer Molecule Type
Non-Small Cell Lung Cancer Products have been categorized under various Molecule types, such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Non-Small Cell Lung Cancer Pipeline Therapeutics Assessment
- Non-Small Cell Lung Cancer Assessment by Product Type
- Non-Small Cell Lung Cancer By Stage and Product Type
- Non-Small Cell Lung Cancer Assessment by Route of Administration
- Non-Small Cell Lung Cancer By Stage and Route of Administration
- Non-Small Cell Lung Cancer Assessment by Molecule Type
- Non-Small Cell Lung Cancer by Stage and Molecule Type
DelveInsight's Non-Small Cell Lung Cancer Report covers around 10+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Non-Small Cell Lung Cancer product details are provided in the report. Download the Non-Small Cell Lung Cancer pipeline report to learn more about the emerging Non-Small Cell Lung Cancer therapies at:
Some of the key companies in the Non-Small Cell Lung Cancer Therapeutics Market include:
Key companies developing therapies for Non-Small Cell Lung Cancer are - Bristol-Myers Squibb, Teligene US, Rain Oncology Inc, ReHeva Biosciences, Inc., Amgen, Novartis, RedCloud Bio, Parexel, Vitrac Therapeutics, LLC, Mythic Therapeutics, Instil Bio, Mirati Therapeutics Inc., Daiichi Sankyo, Inc., AstraZeneca, Precision Biologics, Inc, Promontory Therapeutics Inc., Palobiofarma SL, Regeneron Pharmaceuticals, EMD Serono, Merck, Cellular Biomedicine Group, Inc., Celgene, CellSight Technologies, Inc., BeyondSpring Pharmaceuticals Inc., J Ints Bio, Forward Pharmaceuticals Co., Ltd., AstraZeneca, Revolution Medicines, Inc., Cullinan Oncology, LLC, Iovance Biotherapeutics, Inc., Innate Pharma, and others.
Non-Small Cell Lung Cancer Pipeline Analysis:
The Non-Small Cell Lung Cancer pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Non-Small Cell Lung Cancer with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Small Cell Lung Cancer Treatment.
- Non-Small Cell Lung Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Non-Small Cell Lung Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Small Cell Lung Cancer market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Non-Small Cell Lung Cancer drugs and therapies
Non-Small Cell Lung Cancer Pipeline Market Drivers
- Increasing prevalence of non-small cell lung cancer, increasing launch of pipeline therapies are some of the important factors that are fueling the Non-Small Cell Lung Cancer Market.
Non-Small Cell Lung Cancer Pipeline Market Barriers
- However, high cost of therapies entering the market, requirement of adequate reimbursement policies for NSCLC drugs and other factors are creating obstacles in the Non-Small Cell Lung Cancer Market growth.
Scope of Non-Small Cell Lung Cancer Pipeline Drug Insight
- Coverage: Global
- Key Non-Small Cell Lung Cancer Companies: J INTS BIO BIO CO.,LTD, Mirati Therapeutics, MediLink Therapeutics Co., Ltd., BioNTech SE, Cellular Biomedicine Group, Shenzhen TargetRx, Inc, Iovance Biotherapeutics, Revolution Medicines, Inc., Genmab, Incyte Corporation, Daiichi Sankyo, Novartis Pharmaceutical, and others
- Key Non-Small Cell Lung Cancer Therapies: JIN-A03, MRTX1133, YL202, BNT116, C-TIL051, TGRX-326, LN-145, RMC-4630, GEN1046, Retifanlimab, DS-1062a, JDQ443, and others
- Non-Small Cell Lung Cancer Therapeutic Assessment: Non-Small Cell Lung Cancer current marketed and Non-Small Cell Lung Cancer emerging therapies
- Non-Small Cell Lung Cancer Market Dynamics: Non-Small Cell Lung Cancer market drivers and Non-Small Cell Lung Cancer market barriers
Request for Sample PDF Report for Non-Small Cell Lung Cancer Pipeline Assessment and clinical trials
Table of Contents
1. Non-Small Cell Lung Cancer Report Introduction
2. Non-Small Cell Lung Cancer Executive Summary
3. Non-Small Cell Lung Cancer Overview
4. Non-Small Cell Lung Cancer- Analytical Perspective In-depth Commercial Assessment
5. Non-Small Cell Lung Cancer Pipeline Therapeutics
6. Non-Small Cell Lung Cancer Late Stage Products (Phase II/III)
7. Non-Small Cell Lung Cancer Mid Stage Products (Phase II)
8. Non-Small Cell Lung Cancer Early Stage Products (Phase I)
9. Non-Small Cell Lung Cancer Preclinical Stage Products
10. Non-Small Cell Lung Cancer Therapeutics Assessment
11. Non-Small Cell Lung Cancer Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Non-Small Cell Lung Cancer Key Companies
14. Non-Small Cell Lung Cancer Key Products
15. Non-Small Cell Lung Cancer Unmet Needs
16 . Non-Small Cell Lung Cancer Market Drivers and Barriers
17. Non-Small Cell Lung Cancer Future Perspectives and Conclusion
18. Non-Small Cell Lung Cancer Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email:Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services
